title: Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix.
abstract: The aim of the retrospective study was to evaluate prognostic significance of human papillomavirus (HPV) status and expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor type 2 (HER2/neu), vascular endothelial growth factor (VEGF), CD34 antigen, tumor suppressors p63 and p53, and Ki67/MIB-1 in squamous cell carcinoma of the uterine cervix (SCCC) treated with radiotherapy or chemoradiotherapy. Seventy-two consecutive patients with SCCC, diagnosed and treated with (chemo-) radiotherapy with a curative intent at the University Hospital Hradec Kralove between August 1998 and August 2008, were enrolled in the study. The median follow-up period was 57 months (range 5-152). The tested biological factors were evaluated by polymerase chain reaction (HPV status) and by immunohistochemistry (remaining above mentioned markers) from archival paraffin embedded original diagnostic tumor samples. A statistical significant correlation was observed between low expression of p63 and poor overall survival (p = 0.001), although the complete response probability was influenced with borderline statistical significance (p = 0.05). However, the results could be affected by the statistical error due to the small number of p63 negative patients. HPV positivity and EGFR staining intensity was associated with higher complete response probability (p = 0.038 and p = 0.044, resp.). All other results were not significant. Neither HPV positivity nor EGFR staining intensity were reflected in the overall survival evaluation. In conclusion, the presented study did not confirm any apparently significant association of the suggested markers with prognosis of SCCC in patients treated with (chemo-) radiotherapy.
authors.affiliation: Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Sokolská 581, 500 05, Hradec Kralove, Czech Republic, milan.vosmik@fnhk.cz.
authors.forename: Milan
authors.initials: M
authors.lastname: Vosmik
authors.forename: Jan
authors.initials: J
authors.lastname: Laco
authors.forename: Igor
authors.initials: I
authors.lastname: Sirak
authors.forename: Martin
authors.initials: M
authors.lastname: Beranek
authors.forename: Eva
authors.initials: E
authors.lastname: Hovorkova
authors.forename: Hana
authors.initials: H
authors.lastname: Vosmikova
authors.forename: Monika
authors.initials: M
authors.lastname: Drastikova
authors.forename: Miroslav
authors.initials: M
authors.lastname: Hodek
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Zoul
authors.forename: Karel
authors.initials: K
authors.lastname: Odrazka
authors.forename: Jiri
authors.initials: J
authors.lastname: Petera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy / Q000821:virology*; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D008565:Membrane Proteins / Q000235:genetics; D008875:Middle Aged; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000235:genetics / Q000473:pathology / Q000821:virology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy / Q000821:virology*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
chemical_list: D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D019394:Ki-67 Antigen; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; C081876:CKAP4 protein, human; C467484:VEGFA protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human
references.citation: Cancer. 2001 Jan 1;91(1):80-9
references.pmid: 11148563
references.citation: Gynecol Oncol. 2008 Mar;108(3):555-60
references.pmid: 18199473
references.citation: Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1345-51
references.pmid: 11955748
references.citation: Gynecol Oncol. 2004 Sep;94(3):636-42
references.pmid: 15350352
references.citation: Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):973-82
references.pmid: 22898381
references.citation: BMC Cancer. 2008 Aug 12;8:232
references.pmid: 18700025
references.citation: Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1165-72
references.pmid: 19101092
references.citation: Anticancer Res. 2007 May-Jun;27(3B):1609-15
references.pmid: 17595784
references.citation: Int J Gynecol Cancer. 2005 Mar-Apr;15(2):278-84
references.pmid: 15823112
references.citation: Int J Gynecol Pathol. 1996 Jan;15(1):23-7
references.pmid: 8852442
references.citation: Br J Cancer. 2000 Sep;83(5):620-5
references.pmid: 10944602
references.citation: Gynecol Oncol. 2009 Mar;112(3):583-9
references.pmid: 19110305
references.citation: Cancer. 2000 Jun 15;88(12):2766-73
references.pmid: 10870059
references.citation: Gynecol Oncol. 2003 Nov;91(2):346-53
references.pmid: 14599865
references.citation: J Korean Med Sci. 2004 Oct;19(5):693-7
references.pmid: 15483346
references.citation: Gynecol Oncol. 2003 Jan;88(1):22-8
references.pmid: 12504622
references.citation: Ceska Gynekol. 2006 Jul;71(4):308-11
references.pmid: 16956043
references.citation: Lancet. 2001 Sep 8;358(9284):781-6
references.pmid: 11564482
references.citation: Acta Medica (Hradec Kralove). 2008;51(2):95-9
references.pmid: 18998360
references.citation: Ceska Gynekol. 2007 Apr;72(2):126-30
references.pmid: 17639735
references.citation: Gynecol Oncol. 1996 Nov;63(2):216-8
references.pmid: 8910630
references.citation: Radiother Oncol. 1995 Oct;37(1):1-9
references.pmid: 8539450
references.citation: Gynecol Oncol. 2000 Nov;79(2):300-4
references.pmid: 11063661
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):922-8
references.pmid: 12829126
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7389-97
references.pmid: 19920104
references.citation: J Pathol. 1999 Sep;189(1):1-3
references.pmid: 10451480
references.citation: Cancer Detect Prev. 1998;22(2):120-8
references.pmid: 9544432
references.citation: Gynecol Oncol. 2005 Nov;99(2):415-21
references.pmid: 16157365
references.citation: J Cancer Res Clin Oncol. 1998;124(8):456-61
references.pmid: 9750023
references.citation: Neoplasma. 2011;58(6):469-75
references.pmid: 21895399
references.citation: Int J Gynecol Cancer. 2003 Nov-Dec;13(6):849-55
references.pmid: 14675323